JP7665339B2 - 既存の相互作用を最小化する改変結合分子 - Google Patents

既存の相互作用を最小化する改変結合分子 Download PDF

Info

Publication number
JP7665339B2
JP7665339B2 JP2020572773A JP2020572773A JP7665339B2 JP 7665339 B2 JP7665339 B2 JP 7665339B2 JP 2020572773 A JP2020572773 A JP 2020572773A JP 2020572773 A JP2020572773 A JP 2020572773A JP 7665339 B2 JP7665339 B2 JP 7665339B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
sequence
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020572773A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021531245A5 (https=
JPWO2020014358A5 (https=
JP2021531245A (ja
Inventor
サムナー ジアンヌ
チェン チーホア
パートリッジ マイケル
トッリ アルバート
ラジャドヒャクシャ マノジュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2021531245A publication Critical patent/JP2021531245A/ja
Publication of JP2021531245A5 publication Critical patent/JP2021531245A5/ja
Publication of JPWO2020014358A5 publication Critical patent/JPWO2020014358A5/ja
Priority to JP2025064335A priority Critical patent/JP2025100662A/ja
Application granted granted Critical
Publication of JP7665339B2 publication Critical patent/JP7665339B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020572773A 2018-07-10 2019-07-10 既存の相互作用を最小化する改変結合分子 Active JP7665339B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025064335A JP2025100662A (ja) 2018-07-10 2025-04-09 既存の相互作用を最小化する改変結合分子

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862695988P 2018-07-10 2018-07-10
US62/695,988 2018-07-10
PCT/US2019/041203 WO2020014358A1 (en) 2018-07-10 2019-07-10 Modifying binding molecules to minimize pre-existing interactions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025064335A Division JP2025100662A (ja) 2018-07-10 2025-04-09 既存の相互作用を最小化する改変結合分子

Publications (4)

Publication Number Publication Date
JP2021531245A JP2021531245A (ja) 2021-11-18
JP2021531245A5 JP2021531245A5 (https=) 2022-07-20
JPWO2020014358A5 JPWO2020014358A5 (https=) 2022-07-20
JP7665339B2 true JP7665339B2 (ja) 2025-04-21

Family

ID=67544330

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020572773A Active JP7665339B2 (ja) 2018-07-10 2019-07-10 既存の相互作用を最小化する改変結合分子
JP2025064335A Pending JP2025100662A (ja) 2018-07-10 2025-04-09 既存の相互作用を最小化する改変結合分子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025064335A Pending JP2025100662A (ja) 2018-07-10 2025-04-09 既存の相互作用を最小化する改変結合分子

Country Status (16)

Country Link
US (2) US11448651B2 (https=)
EP (1) EP3820891A1 (https=)
JP (2) JP7665339B2 (https=)
KR (1) KR102938177B1 (https=)
CN (1) CN112543768B (https=)
AR (1) AR115730A1 (https=)
AU (1) AU2019302642B2 (https=)
BR (1) BR112020026784A2 (https=)
CA (1) CA3104873A1 (https=)
EA (1) EA202190228A1 (https=)
IL (2) IL316308A (https=)
MX (2) MX2021000239A (https=)
MY (1) MY202673A (https=)
SG (1) SG11202012835RA (https=)
TW (2) TW202428612A (https=)
WO (1) WO2020014358A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019302642B2 (en) 2018-07-10 2025-10-30 Regeneron Pharmaceuticals, Inc. Modifying binding molecules to minimize pre-existing interactions
US20260008857A1 (en) * 2024-06-13 2026-01-08 Flagship Pioneering Innovations Vi, Llc Antigen Binding Molecules Targeting Interleukine-4 Receptor Subunit Alpha (IL-4Ra)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012507294A (ja) 2008-10-29 2012-03-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−４受容体に対する高親和性ヒト抗体
JP2017532570A (ja) 2014-11-05 2017-11-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ エフェクター機能抑制型ヒトまたはヒト化薬物抗体に対する抗薬物抗体の決定方法
JP2017535547A (ja) 2014-11-14 2017-11-30 サノフィ・バイオテクノロジー Ｉｌ−４ｒアンタゴニストの投与により鼻ポリープを伴う慢性副鼻腔炎を処置する方法
US20180092975A1 (en) 2016-09-19 2018-04-05 Celgene Corporation Methods of treating immune disorders using pd-1 binding proteins

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
US6056957A (en) * 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU2004245038A1 (en) 2003-06-02 2004-12-16 Alexion Pharmaceuticals, Inc. De-immunized anti-CD3 antibody
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
CA2644663A1 (en) 2006-03-23 2007-09-27 Kirin Pharma Kabushiki Kaisha Agonist antibody to human thrombopoietin receptor
AU2008348252A1 (en) 2008-01-15 2009-07-23 Stichting Sanquin Bloedvoorziening Method and kits for detecting antibodies against therapeutic antibodies
CN105218673A (zh) * 2008-10-10 2016-01-06 新兴产品开发西雅图有限公司 Tcr复合物免疫治疗剂
CA2741114A1 (en) 2008-10-24 2010-04-29 Cornelis Lammert Verweij Biomarkers for predicting the development of chronic autoimmune diseases
DE102008061522A1 (de) 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
WO2010122148A1 (en) 2009-04-24 2010-10-28 Boehringer Ingelheim International Gmbh An improved antibody domain and antibody fragments and antibodies based thereon
JP5816170B2 (ja) 2009-06-26 2015-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
WO2011074965A1 (en) 2009-12-17 2011-06-23 Stichting Sanquin Bloedvoorziening Methods and means for counteracting an activity of an fc domain
WO2012166588A2 (en) 2011-06-01 2012-12-06 Morehouse School Of Medicine Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
SG2014010482A (en) * 2011-08-17 2014-04-28 Glaxo Group Ltd Modified proteins and peptides
TW201444872A (zh) 2013-03-06 2014-12-01 Merrimack Pharmaceuticals Inc 抗Ｃ－ＭＥＴ串聯Ｆｃ雙特異性抗體
TWI755763B (zh) * 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
EA034666B1 (ru) 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
CA2950155C (en) 2014-06-02 2021-11-23 Regeneron Pharmaceuticals, Inc. Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses
CN117442748A (zh) 2014-10-02 2024-01-26 希望之城公司 多价中间表位、中间表位结合抗体及其用途
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
AU2016344665C1 (en) * 2015-10-29 2023-07-27 F. Hoffmann-La Roche Ag Anti-variant Fc-region antibodies and methods of use
US20170137535A1 (en) 2015-10-30 2017-05-18 Genentech, Inc. Anti-factor d antibody formulations
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
WO2019101863A1 (en) 2017-11-22 2019-05-31 Vacara Ab Antibodies to citrullinated proteins
AU2019302642B2 (en) 2018-07-10 2025-10-30 Regeneron Pharmaceuticals, Inc. Modifying binding molecules to minimize pre-existing interactions
WO2020246891A1 (en) 2019-06-07 2020-12-10 Sanquin Innovatie B.V. Methods and compounds for typing rheumatoid factors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012507294A (ja) 2008-10-29 2012-03-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−４受容体に対する高親和性ヒト抗体
JP2017532570A (ja) 2014-11-05 2017-11-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ エフェクター機能抑制型ヒトまたはヒト化薬物抗体に対する抗薬物抗体の決定方法
JP2017535547A (ja) 2014-11-14 2017-11-30 サノフィ・バイオテクノロジー Ｉｌ−４ｒアンタゴニストの投与により鼻ポリープを伴う慢性副鼻腔炎を処置する方法
US20180092975A1 (en) 2016-09-19 2018-04-05 Celgene Corporation Methods of treating immune disorders using pd-1 binding proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of Immunology Research，2016年，Article ID 2618575
Journal of Immunology Research，2016年，Article ID 5069678

Also Published As

Publication number Publication date
AU2019302642A1 (en) 2021-02-25
EP3820891A1 (en) 2021-05-19
CN112543768A (zh) 2021-03-23
KR102938177B1 (ko) 2026-03-11
EA202190228A1 (ru) 2021-04-14
MX2021000239A (es) 2021-03-25
US12523659B2 (en) 2026-01-13
SG11202012835RA (en) 2021-01-28
CN112543768B (zh) 2024-05-03
AU2019302642B2 (en) 2025-10-30
US20200018754A1 (en) 2020-01-16
WO2020014358A1 (en) 2020-01-16
MY202673A (en) 2024-05-14
AR115730A1 (es) 2021-02-17
TW202428612A (zh) 2024-07-16
IL279803A (en) 2021-03-01
US11448651B2 (en) 2022-09-20
IL316308A (en) 2024-12-01
TWI838388B (zh) 2024-04-11
MX2025013509A (es) 2025-12-01
JP2021531245A (ja) 2021-11-18
CA3104873A1 (en) 2020-01-16
TW202021984A (zh) 2020-06-16
JP2025100662A (ja) 2025-07-03
US20230266333A1 (en) 2023-08-24
BR112020026784A2 (pt) 2021-03-30
KR20210030378A (ko) 2021-03-17

Similar Documents

Publication Publication Date Title
JP7442581B2 (ja) ヒトｉｌ－４受容体に対する高親和性ヒト抗体
US8613927B2 (en) High affinity human antibodies to human nerve growth factor
CN102574923B (zh) 针对人蛋白酶激活受体-2的高亲和力人抗体
JP2025100662A (ja) 既存の相互作用を最小化する改変結合分子
EA047574B1 (ru) Модификация связывающих молекул для минимизации уже существующих взаимодействий
EA045437B1 (ru) Антитела человека к bet v 1 и способы их применения
EA040089B1 (ru) Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение
HK1144379B (en) High affinity human antibodies to human nerve growth factor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220708

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250311

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250409

R150 Certificate of patent or registration of utility model

Ref document number: 7665339

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150